43 results match your criteria: "Proteogenomics Research Institute for Systems Medicine[Affiliation]"
Int J Mol Sci
November 2024
Proteogenomics Research Institute for Systems Medicine (PRISM), 505 Coast Blvd. South, La Jolla, CA 92037, USA.
Dalton Trans
November 2024
Department of Chemistry, The University of Houston, 4800 Calhoun Road, Houston, Texas 77004, USA.
We report an aniline ligand (1) with two (pyrazolyl)alkane arms, and its cationic, dizinc complexes. XRD, NMR, and modelling of the dizinc complexes resulted in an unprecedented, dynamic μ-anilide core. Compared with published μ-phenolate analogues, our μ-anilide complexes show higher activity and divergent counterion trends in ring-opening polymerization of -lactide.
View Article and Find Full Text PDFCells
March 2024
Proteogenomics Research Institute for Systems Medicine (PRISM), 505 Coast Blvd. South, La Jolla, CA 92037, USA.
Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease characterized by the relentless deposition of extracellular matrix (ECM), causing lung distortions and dysfunction. Animal models of human IPF can provide great insight into the mechanistic pathways underlying disease progression and a means for evaluating novel therapeutic approaches. In this study, we describe the effect of bleomycin concentration on disease progression in the classical rat bleomycin model.
View Article and Find Full Text PDFAnal Chem
February 2024
Department of Chemistry, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, USA.
Large immune complexes formed by the cross-linking of antibodies with polyvalent antigens play critical roles in modulating cell-mediated immunity. While both the size and the shape of immune complexes are important determinants in Fc receptor-mediated signaling responsible for phagocytosis, degranulation, and, in some instances, autoimmune pathologies, their characterization remains extremely challenging due to their large size and structural heterogeneity. We use native mass spectrometry (MS) supplemented with limited charge reduction in the gas phase to determine the stoichiometry of immune complexes formed by a bivalent (homodimeric) antigen, a 163 kDa aminopeptidase P2 (APP2), and a monoclonal antibody (mAb) to APP2.
View Article and Find Full Text PDFPharmacology
January 2024
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, USA.
Introduction: We investigated the potential of LPS (10-300 µg/rat) administered intratracheally (i.t.) to induce reproducible features of acute lung injury (ALI) and compared the pharmacological efficacy of anti-inflammatory glucocorticoids and antifibrotic drugs to reduce the disease.
View Article and Find Full Text PDFObjectives: Obesity and old age are commonly assumed to be risk factors for COVID-19 mortality. On a worldwide basis, we examine quantitative measures of obesity and elderly in the populations of individual countries and territories, and investigate whether these measures are predictive of COVID-19 mortality in those countries. In particular, we highlight regional differences relative to obesity and elderly metrics, and how these relate to COVID-19 mortality.
View Article and Find Full Text PDFMed Res Arch
April 2023
Proteogenomics Research Institute for Systems Medicine, La Jolla, California 92037, USA.
Objectives: We investigate governmental responses to the COVID-19 pandemic on a statewide basis between January 2020 and June 2022, together with mortality rates attributable to COVID-19 over the same period. Our aim is to demarcate the states' responses, and examine whether these differential responses are associated with COVID-19 mortality.
Methods: Our study is based on individual state data from the Oxford COVID-19 Government Response Tracker, OxCGRT.
Chem Sci
March 2023
National Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University Wuhan 430079 China
Although metallacycle-based photosensitizers have attracted increasing attention in biomedicine, their clinical application has been hindered by their inherent dark toxicity and unsatisfactory phototherapeutic efficiency. Herein, we employ a π-expansion strategy for ruthenium acceptors to develop a series of Ru(ii) metallacycles (Ru1-Ru4), while simultaneously reducing dark toxicity and enhancing phototoxicity, thus obtaining a high phototoxicity index (PI). These metallacycles enable deep-tissue (∼7 mm) fluorescence imaging and reactive oxygen species (ROS) production and exhibit remarkable anti-tumor activity even under hypoxic conditions.
View Article and Find Full Text PDFPhysiol Rep
March 2023
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, USA.
The aim of this study was to describe and characterize the pathophysiological changes occurring during the early inflammatory phase (first 3 days) in the rat bleomycin model of lung injury preceding the development of fibrosis. Further, we wanted to understand the kinetics and factors contributing to bleomycin-induced acute lung injury (ALI) and provide a robust, reliable and reproducible framework of features of ALI readouts to assess effects of therapeutics on bleomycin-induced ALI in rats. We induced ALI in rats with intratracheal (i.
View Article and Find Full Text PDFPLoS One
November 2022
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, United States of America.
The long-sought-after "magic bullet" in systemic therapy remains unrealized for disease targets existing inside most tissues, theoretically because vascular endothelium impedes passive tissue entry and full target engagement. We engineered the first "dual precision" bispecific antibody with one arm pair to precisely bind to lung endothelium and drive active delivery and the other to precisely block TGF-β effector function inside lung tissue. Targeting caveolae for transendothelial pumping proved essential for delivering most of the injected intravenous dose precisely into lungs within one hour and for enhancing therapeutic potency by >1000-fold in a rat pneumonitis model.
View Article and Find Full Text PDFHeliyon
April 2022
Proteogenomics Research Institute for Systems Medicine, La Jolla, California, United States.
Background: Examination of the mortality patterns in the United States among racial, ethnic, and age groups attributed to the 1918-19 influenza pandemic revealed stark disparities, causes for which could have been addressed and rectified this past century. However, these disparities have been amplified during the current COVID-19 pandemic.We have ignored the lessons of the past, and were destined to repeat its failings.
View Article and Find Full Text PDFBiomed Res Int
January 2022
Vaccine Research Institute of San Diego (VRISD), San Diego Science Center, 3030 Bunker Hill, San Diego, CA 92109, USA.
J Infect Dis Epidemiol
July 2021
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, USA.
Background: Annual influenza outbreaks constitute a major public health concern, both in the United States and worldwide. Comparisons of the health burdens of outbreaks might lead to the identification of specific at-risk populations, for whom public health resources should be marshaled appropriately and equitably.
Methods: We examined the disease burden of the 2009-10 influenza A (H1N1) pandemic relating to illnesses, medical visits, hospitalizations, and mortality, compared to influenza seasons 2010 to 2019, in the United States, as compiled by the Centers for Disease Control.
Value Health
July 2021
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Objectives: Throughout the coronavirus disease 2019 pandemic, susceptible-infectious-recovered (SIR) modeling has been the preeminent modeling method to inform policy making worldwide. Nevertheless, the usefulness of such models has been subject to controversy. An evolution in the epidemiological modeling field is urgently needed, beginning with an agreed-upon set of modeling standards for policy recommendations.
View Article and Find Full Text PDFGlob J Epidemol Infect Dis
November 2021
Proteogenomics Research Institute for Systems Medicine, La Jolla, California, USA.
Background: Annual influenza outbreaks constitute a major public health concern in the United States. But this health burden appears dwarfed by the impact of COVID-19. Our aim is to quantify the excess mortality attributable to COVID-19, compared to previous influenza seasons.
View Article and Find Full Text PDFArch Cancer Biol Ther
June 2020
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California 92037, USA.
Background: We have recently introduced a modification of the seminal Simeoni model for tumor growth, the modification entailing the incorporation of delay differential equations into its formulation. We found that the modification was competitive with the Simeoni construct in modeling mammary tumor growth under cisplatin treatment in an animal model.
Methods: In our original study, we had two cohorts of animals: untreated, and treatment with bolus injection of cisplatin on day 0.
ChemMedChem
July 2020
Vaccine Research Institute of San Diego (VRISD), 3030 Bunker Hill Street, San Diego, CA 92109, USA.
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a small molecule with potent anticancer activity. Like other 1,4-naphthoquinones, it exhibits electrophilic reactivity towards biological nucleophiles. We demonstrate that plumbagin and structurally related 1,4-naphthoquinones with at least one unsubstituted quinoid carbon (C2 or C3) bind to albumin, an ubiquitously present nucleophile, with minimum recovery of free drug.
View Article and Find Full Text PDFBMC Cancer
March 2020
Proteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, 92037, USA.
Background: Simeoni and colleagues introduced a compartmental model for tumor growth that has proved quite successful in modeling experimental therapeutic regimens in oncology. The model is based on a system of ordinary differential equations (ODEs), and accommodates a lag in therapeutic action through delay compartments. There is some ambiguity in the appropriate number of delay compartments, which we examine in this note.
View Article and Find Full Text PDFProteomics
August 2018
Proteogenomics Research Institute for Systems Medicine, 92037, La Jolla, CA, USA.
J Control Release
December 2017
Proteogenomics Research Institute for Systems Medicine, 505 Coast Blvd. South, La Jolla, CA 92037, United States. Electronic address:
Poor delivery efficiency continues to hamper the effectiveness of cancer therapeutics engineered to destroy solid tumors using different strategies such as nanocarriers, targeting agents, and matching treatments to specific genetic mutations. All contemporary systemic anti-cancer agents are dependent upon passive transvascular mechanisms for their delivery into solid tumors. The therapeutic efficacies of our current drug arsenal could be significantly improved with an active delivery strategy.
View Article and Find Full Text PDFClin Transl Med
March 2016
Theodor-Billroth-Academy®, Munich, Germany.
One major objective for our evolving understanding in the treatment of cancers will be to address how a combination of diagnosis and treatment strategies can be used to integrate patient and tumor variables with an outcome-oriented approach. Such an approach, in a multimodal therapy setting, could identify those patients (1) who should undergo a defined treatment (personalized therapy) (2) in whom modifications of the multimodal therapy due to observed responses might lead to an improvement of the response and/or prognosis (individualized therapy), (3) who might not benefit from a particular toxic treatment regimen, and (4) who could be identified early on and thereby be spared the morbidity associated with such treatments. These strategies could lead in the direction of precision medicine and there is hope of integrating translational molecular data to improve cancer classifications.
View Article and Find Full Text PDFMol Cell Proteomics
December 2014
§Université de Bordeaux, Bordeaux, France; ¶INSERM, UMR-U1053, Team ≪ Endoplasmic Reticulum Stress and Cancer ≫, Bordeaux, France. ‖BMYscreen, Bordeaux, France; Centre Régional de Lutte Contre le Cancer Eugène Marquis, 35000 Rennes, France
Nat Med
September 2014
1] Proteogenomics Research Institute for Systems Medicine, San Diego, California, USA. [2] Sidney Kimmel Cancer Center, San Diego, California, USA.
Technologies are needed to map and image biological barriers in vivo that limit solid tumor delivery and, ultimately, the effectiveness of imaging and therapeutic agents. Here we integrate proteomic and imaging analyses of caveolae at the blood-tumor interface to discover an active transendothelial portal to infiltrate tumors. A post-translationally modified form of annexin A1 (AnnA1) is selectively concentrated in human and rodent tumor caveolae.
View Article and Find Full Text PDFMost cancer patients die of metastatic disease, not primary tumors, while biological mechanisms leading to metastases remain unclear and effective therapies are missing. Using a mouse dorsal skin chamber model we had observed that tumor growth and vasculature formation could be influenced by the way in vitro cultured (avascular) spheroids of N202 breast tumor cells were implanted; co-implantation of lactating breast tissue created stimulating microenvironment, whereas the absence of the graft resulted in temporary tumor dormancy. This report addressed the issue of cellular mechanisms of the vasculogenic switch that ended the dormancy.
View Article and Find Full Text PDF